This event has already taken place.
Any recording and slides are available to ShareSoc members. Log in or join to access.
Company: Faron Pharmaceuticals (FARN)
Date: 3rd November 2020
Time: 5pm start – 6pm finish
Presenter: Markku Jalkanen, CEO
Format: Webinar
Company Information: Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development and is currently in phase I/II. Traumakine, the Company’s pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com
Registration
This is a 3 step process:
1) Log in to your ShareSoc account or Join ShareSoc for free
2) Click ‘Submit’ on the form below
3) Click on the link on the next page to register with GoToWebinar to COMPLETE THE REGISTRATION
Once you have registered fully with GoToWebinar you will receive an email notification, as well as reminders 1 day and 1 hour before the event starts.